All posts by: Michael Zand

About Michael Zand

Stem cell eye treatment safe, restores some vision, study finds – Malay Mail

Continue reading

2018-03-20 NEWS

Malay Mail

Stem cell eye treatment safe, restores some vision, study finds
Malay Mail
The eye is thought to be a promising site for stem cell transplants, as it is behind a shield called the blood-ocular barrier where there is a weaker immune response. ― AFP picLONDON, March 20 ― Two people with severe vision loss due to a
Nature Cell’s stem cell treatment for Alzheimer’s approved in JapanThe Korea Herald
Stem cell eye treatment safe, restores some vision: studyRaw Story
Stem Cell Assay: Market Analysis, Strategies, Segmentation and Forecasts, 2018 to 2025Digital Journal
Pharmaceuticals News –Business Services –Healthcare Trends
all 160 news articles »
Continue reading

2018-03-20 NEWS

Malay Mail

Stem cell eye treatment safe, restores some vision, study finds
Malay Mail
The eye is thought to be a promising site for stem cell transplants, as it is behind a shield called the blood-ocular barrier where there is a weaker immune response. ― AFP picLONDON, March 20 ― Two people with severe vision loss due to a
Nature Cell’s stem cell treatment for Alzheimer’s approved in JapanThe Korea Herald
Stem cell eye treatment safe, restores some vision: studyRaw Story
Stem Cell Assay: Market Analysis, Strategies, Segmentation and Forecasts, 2018 to 2025Digital Journal
Pharmaceuticals News –Business Services –Healthcare Trends
all 160 news articles »
Continue reading

2018-03-20 NEWS

Harvard School of Engineering and Applied Sciences

SEAS-developed cancer immunotherapies to be commercialized by …
Harvard School of Engineering and Applied Sciences
A Wyss Institute researcher holds a device that can be loaded with immunotherapy agents designed to stimulate the immune system to attack tumor cells. (Image courtesy of the Wyss Institute at Harvard University). Made of the polymer that’s used in
Novartis taps Harvard tech to advance cancer immunotherapy effortsBioPharma Dive
Novartis, Harvard, Dana-Farber Partner on Biomaterial for Cancer ImmunotherapiesGenetic Engineering & Biotechnology News
Harvard bioengineers’ biomaterial-based cancer immunotherapies to be developed by NovartisPR Newswire (press release)
Investing News Network
all 12 news articles »
Continue reading

2018-03-20 NEWS

Harvard School of Engineering and Applied Sciences

Harvard bioengineers’ biomaterial-based cancer immunotherapies to be developed by Novartis
PR Newswire (press release)
BOSTON, March 20, 2018 /PRNewswire-USNewswire/ — The Wyss Institute for Biologically Inspired Engineering at Harvard University and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) announced today that Novartis will have
SEAS-developed cancer immunotherapies to be commercialized by …Harvard School of Engineering and Applied Sciences
Novartis teams up with Harvard to develop next generation …GlobeNewswire (press release)

all 4 news articles »